Results 121 to 130 of about 105,843 (252)

CD93—An emerging vascular target in cancer therapy

British Journal of Pharmacology, EarlyView.
Abstract CD93 is a single‐pass transmembrane glycoprotein that belongs to the C‐type lectin domain group XIV family of proteins. Although it is known to be expressed in other cell types, namely, in some subsets of immune cells, CD93 is primarily expressed on endothelial cells, where it acts as a crucial regulator of angiogenesis.
Beatriz de Alves Pereira, Stefano Barbera, Roberta Lugano, Anna Dimberg   +3 more
wiley   +1 more source

Possible Effects of Topical Rho-Kinase Inhibitor on Schlemm's Canal Morphology Parameters. [PDF]

Biomedicines
Mukta AS, Tsutsui A, Hamanaka T, Kaidzu S, Kobayashi K, Ishida N, Tanito M.   +6 more
europepmc   +1 more source

Inhibition of leucine‐rich kinase 2 (LRRK2) promotes peripheral axon regeneration via phosphorylation‐network remodelling

British Journal of Pharmacology, EarlyView.
Background and Purpose In contrast to neurons in the central nervous system, neurons in the peripheral nervous system can regenerate axons after injury via activation of a pro‐regenerative transcriptional programme. Pathogenic mutations in leucine‐rich repeat kinase 2 (LRRK2) are the most common genetic cause of Parkinson's disease, and several small ...
Eun‐Hae Jang, Eun Mo Yang, Gil Song, Seung Min Park, Harryn Choi, Jaeyong Kim, Chanil Kim, Yunho Gim, Hyuk‐Joo Jeon, Yewon Cho, Jong Bae Park, Eun‐Mi Hur   +11 more
wiley   +1 more source

Preoperative Use of the Rho Kinase Inhibitor Ripasudil Protects the Corneal Endothelium from Trabeculectomy-Induced Damage. [PDF]

Clin Ophthalmol
Katsura Y, Fujimoto H, Takata M, Yokoyama H, Sekiya T, Gomi F.   +5 more
europepmc   +1 more source

Rho-Kinase Inhibitors as Emerging Targets for Glaucoma Therapy. [PDF]

Ophthalmol Ther, 2023
Wang J, Wang H, Dang Y.
europepmc   +1 more source

Systematic profiling reveals broad G protein coupling and context‐dependent modulation of cyclic AMP by the orphan receptor GPR139

British Journal of Pharmacology, EarlyView.
Background and Purpose G protein‐coupled receptors (GPCRs) are major drug targets, yet many orphan receptors remain poorly characterized. GPR139 has been implicated in CNS disorders, including schizophrenia and depression, but its signalling mechanisms remain unclear.
Boris Trapkov, Hans Bräuner, Alexander Sebastian Hauser   +2 more
wiley   +1 more source

Long non‐coding RNAs at the crossroads of inflammation, cancer and angiogenesis: Molecular mechanisms and their potential as therapeutic targets

British Journal of Pharmacology, EarlyView.
Long non‐coding RNAs (lncRNAs), a broad class of non‐protein‐coding RNAs, are characterized as new regulators of gene expression at the epigenetic, transcriptional, and post‐transcriptional level. Thus, lncRNAs are involved in the regulation of physiological processes and the development of human diseases and cancer by modulating proinflammatory ...
Charlie Leboff, Pamela Calle‐Mendoza, Maria Hatziapostolou, Christos Polytarchou   +3 more
wiley   +1 more source

The c‐Src inhibitor eCF506 diminishes opioid tolerance and reduces β‐arrestin2 recruitment

British Journal of Pharmacology, EarlyView.
Morphine activation of μ receptors causes tolerance through c‐Src activation and β‐arrestin2 recruitment. c‐Src inhibition or degradation reduces β‐arrestin2 recruitment, μ receptor endocytosis, while causing receptor upregulation, all likely contributing to reduced morphine tolerance.
Samuel Singleton, Fraser Nunn, Erika Lace, Álvaro Lorente‐Macías, Rachel Toth, Asier Unciti‐Broceta, Tim G. Hales   +6 more
wiley   +1 more source

Rho-Kinase Inhibitors: The Application and Limitation in Management of Glaucoma. [PDF]

Biomedicines
Chao YP, Chiu TH, Lu DW.
europepmc   +1 more source

Australian and New Zealand Glaucoma Society (ANZGS) Consensus on Interventional Glaucoma

Clinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background Traditional reactive ‘wait and see’ approaches in glaucoma management often result in unacceptable rates of permanent vision loss. This consensus defines a proactive ‘interventional glaucoma’ framework tailored for the Australian and New Zealand healthcare context. Methods A modified Delphi consensus process was utilised, consisting
Graham A. Lee, Lance Liu, Ridia Lim, Rajiv Shah, Robert J. Casson, Keith R. Martin, Helen Danesh‐Meyer, Ashish Agar, Jennifer C. Fan Gaskin, Judy Y. Ku, Geoffrey Chan, Anna Galanopoulos, Shamira Perera   +12 more
wiley   +1 more source